Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX112 in Refractory Autoimmune Disease
NCT06925542Phase 1Recruiting
- Sponsor
- CRISPR Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2031
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of zugocabtagene geleucel in systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and idiopathic inflammatory myopathy (IIM), sponsored by CRISPR Therapeutics. Primary endpoint: Safety and Tolerability at 28 days. Started Mar 2025; status: recruiting.
02
Drugs
zugocabtagene geleucel
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT06925542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925542.